Cingulate Stock Price To Earnings To Growth
| CING Stock | USD 4.93 0.05 1.00% |
Cingulate fundamentals help investors to digest information that contributes to Cingulate's financial success or failures. It also enables traders to predict the movement of Cingulate Stock. The fundamental analysis module provides a way to measure Cingulate's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cingulate stock.
Cingulate | Price To Earnings To Growth |
Cingulate Company Price To Earnings To Growth Analysis
Cingulate's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Cingulate Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Cingulate is extremely important. It helps to project a fair market value of Cingulate Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Cingulate's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cingulate's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cingulate's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Cingulate Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Cingulate has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Cingulate ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cingulate's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cingulate's managers, analysts, and investors.Environmental | Governance | Social |
Cingulate Fundamentals
| Return On Equity | -2.74 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | 5.55 M | ||||
| Shares Outstanding | 3.21 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 1.55 % | ||||
| Number Of Shares Shorted | 108.41 K | ||||
| Price To Book | 1.28 X | ||||
| Gross Profit | (9 M) | ||||
| EBITDA | (22.95 M) | ||||
| Net Income | (23.53 K) | ||||
| Cash And Equivalents | 8.2 M | ||||
| Cash Per Share | 0.73 X | ||||
| Total Debt | 3.14 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 10.94 X | ||||
| Book Value Per Share | 6.82 X | ||||
| Cash Flow From Operations | (15.04 M) | ||||
| Short Ratio | 1.13 X | ||||
| Earnings Per Share | (43.22) X | ||||
| Target Price | 48.33 | ||||
| Number Of Employees | 13 | ||||
| Beta | -0.91 | ||||
| Market Capitalization | 15.35 M | ||||
| Total Asset | 3.49 M | ||||
| Retained Earnings | (92.94 M) | ||||
| Working Capital | 856.85 K | ||||
| Net Asset | 3.49 M |
About Cingulate Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cingulate's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cingulate using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cingulate based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C | |
| FMC | FMC Corporation | |
| XYF | X Financial Class |
Check out Cingulate Piotroski F Score and Cingulate Altman Z Score analysis. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.